Alpha Healthcare Acquisition III Shares Resume Trade
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the successful completion of its business combination (the "Business Combination") with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications ("Carmell"). The resulting combined company, Carmell Therapeutics Corporation, is expected to commence trading of its shares of common stock and warrants on the Nasdaq Capital Market® under the ticker symbols "CTCX" and "CTCXW," respectively, on July 17, 2023.
Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a non-binding letter of intent (the "LOI") to acquire a commercial stage regenerative medicine company (the "Target") conditioned upon the closing of ALPA's initial business combination with Carmell Therapeutics Corporation, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications ("Carmell"). ALPA has set a Stockholders Meeting (the "Meeting") to consider the previously announced business combination with Carmell for J
Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) ("ALPA"), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a definitive business combination agreement with Carmell Therapeutics Corporation ("Carmell™"), a Phase 2-stage biotechnology platform company developing allogeneic plasma-based biomaterials for bone and soft tissue healing indications. Upon closing of the transaction, ALPA will be renamed Carmell Therapeutics Corporation (the "Combined Company"). Mr. Shukla will serve as Chairman and Mr. Randy Hubbell will serve as Chief Executive Officer of the Combined Company. The Combined Company's common stock is expected to be listed on the Na
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
4 - Carmell Corp (0001842939) (Issuer)
8-K - Carmell Corp (0001842939) (Filer)
8-K - Carmell Corp (0001842939) (Filer)
8-K - Carmell Corp (0001842939) (Filer)
SC 13G/A - Carmell Corp (0001842939) (Subject)
SC 13G/A - Carmell Corp (0001842939) (Subject)
SC 13G - Carmell Corp (0001842939) (Subject)